Abstract
Combination lovastatin and probucol reduced total cholesterol (27%) and low-density lipoprotein levels (30%), but did not prevent restenosis or clinical events during the first 6 months after percutaneous transluminal coronary angioplasty.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Angioplasty, Balloon, Coronary*
-
Anticholesteremic Agents / therapeutic use*
-
Constriction, Pathologic
-
Coronary Disease / blood
-
Coronary Disease / surgery*
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
Humans
-
Lipoproteins / blood
-
Lovastatin / therapeutic use*
-
Male
-
Middle Aged
-
Probucol / therapeutic use*
-
Recurrence
Substances
-
Anticholesteremic Agents
-
Lipoproteins
-
Lovastatin
-
Probucol